Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 17 (2), 234-242, 2016-02
Elsevier BV